<DOC>
	<DOCNO>NCT01542736</DOCNO>
	<brief_summary>To study efficacy combination reduce dose craniospinal radiation ( reduce standard care dose 36 Gy 24 Gy ) concurrent carboplatin vincristine administration metastatic classical histology medulloblastomas high-risk supratentorial PNETs metastatic PNETs .</brief_summary>
	<brief_title>Concurrent Carboplatin Reduced Dose Craniospinal Radiation Medulloblastoma Primitive Neuroectodermal Tumor ( PNET )</brief_title>
	<detailed_description />
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age great 3 year less 25 year Patients classic histology desmoplastic histology metastatic medulloblastoma histological diagnosis head spine MRI . Patients anaplastic histology exclude . Patients highrisk supratentorial , nonmetastatic , PNET Patients metastatic PNET Newly diagnose patient receive prior therapy , exception one short course emergent chemotherapy newly present patient neurological compromise per provider decision Only patient expect survive least 6 week eligible study . Patients pregnant may treat study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>